Double-Blind, Placebo-Controlled, Randomized Clinical Trial Demonstrates Telomerase Activator TA-65 Decreases Immunosenescent CD8+CD28- T Cells in Humans

安慰剂 随机对照试验 医学 CD8型 内科学 CD28 免疫衰老 胃肠病学 安慰剂对照研究 双盲 免疫学 免疫系统 病理 替代医学
作者
Gunasekaran Singaravelu,Calvin B. Harley,Joseph M. Raffaele,Pratheesh Sudhakaran,Anitha Suram
出处
期刊:OBM geriatrics [LIDSEN Publishing Inc]
卷期号:05 (02): 1-1 被引量:5
标识
DOI:10.21926/obm.geriatr.2102168
摘要

TA-65 is a small molecule telomerase activator extracted from Astragalus species. A previous observational study suggested that TA-65 decreased the number of immunosenescent cells in healthy subjects. Here we examined the impact of TA-65 in a much larger randomized, double-blind, and placebo-controlled study. This study aims to evaluate the effects of TA-65 on senescent CD8+CD28- T cells in healthy subjects. This was a randomized, double-blind, placebo-controlled, and multi-arm parallel trial in 500 healthy subjects. Subjects, clinical staff, and primary outcome assessors were blinded until the database lock. A total of 500 healthy volunteers were randomly allocated, 100 subjects each, into one of the five groups; placebo, TA-65 (100 Units) qd, TA-65 (250 Units) qd, TA-65 (500 Units) qd, or TA-65 (250 Units) b.i.d. Change in the immunosenescence biomarker after nine months was measured. The intention-to-treat analysis of the primary outcome measure included all the randomized subjects (n = 500). Per-protocol analysis of the primary outcome measured included 93% of the randomized subjects (n = 424). Multilevel analysis revealed a significant decrease in the CD8+CD28- T cells with TA-65 intervention compared to the placebo group (p<0.05). Intervention by 100 units and 250 units of TA-65 qd led to a decrement of CD8+CD28- T cells by 28 cells/μl, while the intervention by 500 units of TA-65 led to a decrement of CD8+CD28- T cells by 22 cells/μl; the placebo intake led to an increment of CD8+CD28- T cells by 4.38 cells/μl. None of the serious adverse events (9) were deemed related or were unlikely to be related to the product. Adverse events (AEs), ranging from mild to moderate severity were, observed in 34.6% of the subjects. Oral intake of TA-65 significantly decreased CD8+CD28- T cells.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Rr发布了新的文献求助10
1秒前
3秒前
小鱼发布了新的文献求助10
3秒前
3秒前
4秒前
太叔开山完成签到,获得积分10
4秒前
5秒前
6秒前
香蕉觅云应助fkdbdy采纳,获得80
7秒前
9秒前
Acc完成签到,获得积分10
9秒前
10秒前
11秒前
科研通AI2S应助99663232采纳,获得30
13秒前
15秒前
小宇发布了新的文献求助10
16秒前
Macong_44713发布了新的文献求助10
17秒前
小张不慌完成签到,获得积分10
17秒前
18秒前
平淡忻完成签到,获得积分10
18秒前
Avalon发布了新的文献求助10
20秒前
英俊的铭应助hyhyhyhy采纳,获得10
21秒前
万能图书馆应助包宇采纳,获得10
22秒前
cdercder应助重要手机采纳,获得10
22秒前
南南发布了新的文献求助20
25秒前
Macong_44713完成签到,获得积分10
25秒前
25秒前
包宇完成签到,获得积分20
29秒前
Avalon完成签到,获得积分10
29秒前
30秒前
可爱的大白菜真实的钥匙完成签到 ,获得积分10
32秒前
灵巧的导师完成签到,获得积分10
34秒前
35秒前
包宇发布了新的文献求助10
35秒前
劲秉应助研研研采纳,获得10
36秒前
39秒前
积极阳光的白羊座完成签到,获得积分10
40秒前
Rr完成签到,获得积分10
40秒前
吴千雨完成签到,获得积分10
41秒前
高分求助中
IZELTABART TAPATANSINE 500
Where and how to use plate heat exchangers 500
Seven new species of the Palaearctic Lauxaniidae and Asteiidae (Diptera) 400
Armour of the english knight 1400-1450 300
Handbook of Laboratory Animal Science 300
Not Equal : Towards an International Law of Finance 260
Beginners Guide To Clinical Medicine (Pb 2020): A Systematic Guide To Clinical Medicine, Two-Vol Set 250
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3711557
求助须知:如何正确求助?哪些是违规求助? 3260041
关于积分的说明 9912247
捐赠科研通 2973411
什么是DOI,文献DOI怎么找? 1630540
邀请新用户注册赠送积分活动 773429
科研通“疑难数据库(出版商)”最低求助积分说明 744274